<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24675993</article-id><article-id pub-id-type="pmc">3967996</article-id><article-id pub-id-type="publisher-id">PONE-D-13-37165</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0091838</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject></subj-group><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Clinical Trials</subject></subj-group></subj-group><subj-group><subject>Critical Care and Emergency Medicine</subject></subj-group><subj-group><subject>Epidemiology</subject><subj-group><subject>Infectious Disease Epidemiology</subject></subj-group></subj-group><subj-group><subject>Health Care</subject><subj-group><subject>Health Care Policy</subject><subj-group><subject>Treatment Guidelines</subject></subj-group></subj-group></subj-group><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject></subj-group></subj-group><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Cardiovascular Procedures</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Design</subject><subj-group><subject>Clinical Research Design</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Ethanol Lock Therapy (E-Lock) in the Prevention of Catheter-Related Bloodstream Infections (CR-BSI) after Major Heart Surgery (MHS): A Randomized Clinical Trial</article-title><alt-title alt-title-type="running-head">Ethanol Lock in the Prevention of Central Catheter</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>P&#x000e9;rez-Granda</surname><given-names>Mar&#x000ed;a Jes&#x000fa;s</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Barrio</surname><given-names>Jos&#x000e9; Mar&#x000ed;a</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hortal</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rinc&#x000f3;n</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rabad&#x000e1;n</surname><given-names>Pablo Martin</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pernia</surname><given-names>Maria Sagrario</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bouza</surname><given-names>Emilio</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Anesthesiology, School of Medicine, Universidad Complutense, Madrid, Spain</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Clinical Microbiology and Infectious Diseases, School of Medicine, Universidad Complutense, Madrid, Spain</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Pharmacy, Hospital General Universitario Gregorio Mara&#x000f1;&#x000f3;n, Madrid, Spain</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Medicine Department, School of Medicine, Universidad Complutense, Madrid, Spain</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Instituto de Investigaci&#x000f3;n Biom&#x000e9;dica Gregorio Mara&#x000f1;&#x000f3;n, Madrid, Spain</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Gupta</surname><given-names>Vineet</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Pittsburgh Medical Center, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>massus@hotmail.es</email> (MJPG); <email>pmunoz@micro.hggm.es</email> (PM)</corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: MJPG EB. Performed the experiments: MJPG JMB PM JH CR PMR MSP EB. Analyzed the data: MJPG JMB PM EB. Contributed reagents/materials/analysis tools: PMR MSP. Wrote the paper: MJPG PM EB. Approved the manuscript: MJPG JMB PM JH CR PMR MSP EB.</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>27</day><month>3</month><year>2014</year></pub-date><volume>9</volume><issue>3</issue><elocation-id>e91838</elocation-id><history><date date-type="received"><day>5</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 P P&#x000e9;rez-Granda et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>P P&#x000e9;rez-Granda et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Lock-therapy with antimicrobials has been used for the treatment and prevention of catheter-related bloodstream infections (CR-BSI). Experiences with Ethanol-Locks (E-locks) have included therapeutic interventions with variable results. Patients undergoing Major Heart Surgery (MHS) are a high-risk population for CR-BSI.The aim of this study was to assess the efficacy and tolerance to E-Locks in the prevention of CR-BSI of patients undergoing MHS.</p></sec><sec><title>Methods and Findings</title><p>This is an academic, prospective, randomized, non-blinded and controlled clinical trial assessing the incidence of CR-BSI of patients with E-locks (E-lock) and the tolerance to the procedure in comparison with patients receiving conventional catheter-care (CCC). Patients undergoing MHS with intravascular catheters for more than 48 hours were randomly assigned into treatment or control group by a computer-generated list of randomly assigned numbers. In the treatment group, all their catheter lumens were locked with an ethanol solution at 70% for two hours, every three days (E-Locks). The control group received conventional catheter-care (CCC).</p><p>Overall, 200 patients with 323 catheters were included in the study, which was stopped after 10 months due to adverse events. Of them, 179 catheters (113 patients) had E-Locks and 144 catheters (87 patients) were CCC. Euroscore Surgical Risk in both groups was 4.04 vs 4.07 p&#x0200a;=&#x0200a;0.94 respectively. The results for the E-Locks and CCC were as follows: Incidence of CR-BSI/1000 days of exposure 2.1 vs 5.2 (p&#x0200a;=&#x0200a;0.33), catheter tip colonization 14 (7.8%) vs 6 (4.2%) patients (p&#x0200a;=&#x0200a;0.17), median length of hospital stay, 15 vs 16 days (p&#x0200a;=&#x0200a;0.77). Seven patients (6.19%), all in the ethanol branch, had to discontinue the trial due to intolerance or adverse events.</p></sec><sec><title>Conclusions</title><p>We do not recommend prophylaxis of CR-BSI with ethanol-lock on a routine basis in patients undergoing Major Heart Surgery.</p></sec><sec><title>Trial Registration</title><p>Clinical Trials.gov <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/results?term=NCT01229592&#x00026;Search=Search">NCT01229592</ext-link>
</p></sec></abstract><funding-group><funding-statement>This study was partially supported by a grant from Fondo de Investigacion Sanitaria, FIS EC07/90653 (Instituto de Salud Carlos III) and by the Rafael del Pino Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Patients undergoing Major Heart Surgery (MHS) are at a high risk of developing Catheter-Related Bloodstream Infections (CR-BSI) leading to a subsequent increase in morbidity and mortality <xref rid="pone.0091838-Kollef1" ref-type="bibr">[1]</xref>&#x02013;<xref rid="pone.0091838-Bouza1" ref-type="bibr">[4]</xref>.</p><p>Efforts developed to eliminate CR-BSI in patients hospitalized in Intensive Care Units (ICU's) have mainly concentrated on mixed ICUs and not specifically on patients following MHS, who usually require more catheters during more prolonged periods of time <xref rid="pone.0091838-Zack1" ref-type="bibr">[5]</xref>&#x02013;<xref rid="pone.0091838-Betjes1" ref-type="bibr">[7]</xref>. The programs addressed to eliminate CR-BSI episodes are mainly based on educational policies and on non-pharmacological measures and, although effective, these programs fail to lead to the disappearance of CR-BSI in most units and are often difficult to maintain for prolonged periods of time <xref rid="pone.0091838-Pronovost1" ref-type="bibr">[8]</xref>, <xref rid="pone.0091838-PalomarMartinez1" ref-type="bibr">[9]</xref>.</p><p>The use of antibiotic lock solutions to treat CR-BSI has been relatively successful in specific situations, such as pediatric patients or home total parenteral nutrition related infections <xref rid="pone.0091838-Opilla1" ref-type="bibr">[10]</xref>&#x02013;<xref rid="pone.0091838-Huang1" ref-type="bibr">[12]</xref>. However, there is a concern about the potential risk of those solutions to induce the development of antibiotic therapeutic resistance <xref rid="pone.0091838-Landry1" ref-type="bibr">[13]</xref>. Ethanol locks (E-locks) were greeted as a potential non-antibiotic alternative for the rescue of infected long-term catheters that were very difficult to substitute in different and disparate populations <xref rid="pone.0091838-Rajpurkar1" ref-type="bibr">[14]</xref>&#x02013;<xref rid="pone.0091838-Broom1" ref-type="bibr">[18]</xref>. E-locks, however, have not been evaluated as a systematic procedure for the prevention of CR-BSI in the short-term use of catheters.</p><p>Our study is a prospective, randomized trial, evaluating the efficacy and tolerance to E-locks in the prevention of CR-BSI and catheter colonization in patients admitted to a specific MHS-ICU.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><p>Our institution is a general reference hospital with 1,550 beds and approximately 55,000 admissions/year during the study period. The Department of Cardiovascular Surgery is a large referral Unit that performs more than 500 MHS procedures annually. The start date of participant recruitment was February, 2,011.</p><sec id="s2a"><title>Study Design</title><p>Our study is a prospective, randomized, academic clinical trial, not funded by pharmaceutical or biotechnology companies. The patient' inclusion criteria were:</p><list list-type="bullet"><list-item><p>-Recent MHS admission with Central Vascular Catheters (CVC) inserted &#x0003e;48 hours.</p></list-item><list-item><p>-Age &#x0003e;18 years.</p></list-item><list-item><p>-No evidence or suspicion of CR-BSI at enrolment: No signs of infection neither general nor at catheter site entrance.</p></list-item><list-item><p>-No history of allergy or intolerance to ethanol or chronic liver disease.</p></list-item><list-item><p>-No pregnancy.</p></list-item></list><p>Patients who gave their informed consent were randomly assigned into two groups: Ethanol group (E-lock) and conventional catheter-care (CCC). Patients assigned to E-locks had CCC plus all catheter lumens locked with 1 ml of an ethanol solution at 70% for a period of 2 hours every three days, until catheter withdrawal. After the two hours, the ethanol was flushed through with 1 mL of saline solution.</p><p>Both groups received CCC according to standard recommendations and all catheters had split-septum connectors <xref rid="pone.0091838-OGrady1" ref-type="bibr">[19]</xref>. All catheters were withdrawn when clinically required and the catheter tips were systematically sent for culture.</p></sec><sec id="s2b"><title>Preparation of the ethanol solution</title><p>The 70% ethanol solution was prepared by the Pharmacy Department as a sterile solution and was produced in 5 ml single dose vials after approval by the Spanish Agency for Medicines and Health Products and as established by the Spanish Legislation (Real Decreto 223/2004-Spain).</p></sec><sec id="s2c"><title>Endpoints of the Study</title><p>The primary endpoint was the incidence of CR-BSI during the admission for Surgery.</p></sec><sec id="s2d"><title>Secondary endpoints were</title><p>1.-The rate of colonization of the skin surrounding the catheter entrance, the hubs and the catheter tips in the E-lock and the CCC group.</p><p>2.-Antibiotic consumption in the two groups.</p><p>3.-Hospital stay, ICU stay and mortality in both groups of patients.</p><p>4.-Tolerance to the ethanol locks.</p></sec><sec id="s2e"><title>Ethics</title><p>The protocol for this trial and the CONSORT checklist are available as supporting information, see <xref ref-type="supplementary-material" rid="pone.0091838.s001">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0091838.s002">Protocol S1</xref>. The Ethics Committee of our institution (Hospital General Universitario Gregorio Mara&#x000f1;&#x000f3;n) approved the study and all patients gave their written informed consent before inclusion in the study.</p></sec><sec id="s2f"><title>Follow-up of patients</title><p>Patients were followed-up daily to check for the presence of infections and adverse reactions by both the physicians of the Department of Anaesthesia and by Infectious Disease specialists participating in the study. Clinical data were recorded according to a pre-established protocol and no further systematic surveillance cultures were performed.</p></sec><sec id="s2g"><title>Pre-surgical information</title><p>Included epidemiological data, underlying diseases and standard scores (ASA, EuroSCORE, Charlson comorbidity index and APACHE II score on admission to the ICU).</p></sec><sec id="s2h"><title>Surgical information</title><p>Included type of surgery, indication, duration, time of cardiopulmonary by-pass, aortic cross-clamp time and antimicrobial prophylaxis. Antimicrobial prophylaxis for surgery consisted of 2 g of cefazolin given before surgery and every 8 hours thereafter for a total of 3 doses (patients who were allergic to cefazolin received 1 g vancomycin before surgery).</p></sec><sec id="s2i"><title>Postsurgical outcome</title><p>Enrolled patients were prospectively followed for the occurrence of CR-BSI until catheter withdrawal, hospital discharge or death. Outcome variables also included antimicrobial use measured as daily defined doses (DDD's), <italic>Clostridium difficile</italic> infection (CDI) episodes, length of ICU stay, ICU mortality, length of hospital stay and mortality at discharge.</p><p>For each intravascular line, the following data were recorded: type of catheter, insertion site, cause of removal, result of tip, skin and hub cultures and presence or absence of CR-BSI. Catheters were made of polyurethane and were non antibiotic coated.</p></sec><sec id="s2j"><title>Data regarding adverse events</title><p>The following data were systematically collected in both populations after the ethanol or conventional locks were flushed: subjective tolerance, catheter obstruction, elevation of liver function enzymes and reasons for catheter withdrawal.</p></sec><sec id="s2k"><title>Definitions</title><p>The definitions of CR-BSI are those detailed in the recent Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection <xref rid="pone.0091838-OGrady1" ref-type="bibr">[19]</xref>. For the purpose of this study we only accepted microbiologically proven CR-BSI considered when the same microorganism was recovered from blood and a catheter tip within less than 8 days. Catheter tip colonization, hub and skin colonization are defined as the presence of &#x02265;15 colony forming units in the semiquantitative culture according to the roll plate technique recommendation <xref rid="pone.0091838-Maki1" ref-type="bibr">[20]</xref>.</p></sec><sec id="s2l"><title>Statistical analysis</title><p>Considering that the previous incidence density of CR-BSI in our unit was 3.7 episodes/1000 catheter-days before the study, in order to be able to detect a difference of 25% between the two groups with 80% power and a 5% level of significance, we estimated that the sample size for the whole study should be 950 patients, divided equally in 475 in each arm.</p><p>Relationships between baseline variables were evaluated for the randomized groups. Basal comparisons between groups were established by clinical relevance according to the CONSORT recommendations <xref rid="pone.0091838-Weller1" ref-type="bibr">[21]</xref>. The qualitative variables appear with their frequency distribution. The quantitative variables were reported as the mean and standard deviation (SD) and as the median and inter-quartile range (IQR) if their distribution was skewed. Continuous variables were compared using the Student's t test for normally distributed variables or median test for non-normally distributed variables. The Chi 2 or Fisher's exact test was used to compare categorical variables. The Kolmogorov-Smirnov test was used to check whether a variable had a normal distribution.</p><sec id="s2l1"><title>Multivariate analysis</title><p>CR-BSI incidence rates (event/1000 days of CVC) between E-lock and CCC group were compared by Cox regression including all the variables statistically or clinically associated with treatment in the univariate analysis. HR (hazard ratio) and 95% CI were also calculated. All statistical tests were two-tailed. The level of significance was set at p&#x0003c;0.05 for all the tests. The statistical analysis was performed with SPSS 12.0 and Stata 9.0 software.</p></sec></sec></sec><sec id="s3"><title>Results</title><p>The study was terminated early due to side effects. During the study period (February 28, 2011 to December, 31, 2011), 408 patients underwent MHS. Of them, 234 gave their informed consent to participate in the study. From these cases, 34 had to be excluded due to different reasons, including patients without CVC at the time of inclusion, death during surgery, early postoperative deaths, suspicion of infection immediately before the lock administration, or consent withdraw. The remaining 200 patients constitute the Intention to Treat Population (ITT) and 198 the Per-Protocol Population (PP). Only 2 patients failed to receive at least 1 dose of ethanol lock. The statistical analysis performed in both populations (ITT and PP) rendered similar results. The results of the ITT cohort are the ones shown in the manuscript. The patients in the study were randomized to the E-lock (113 patients) or CCC (87 patients) (<xref ref-type="fig" rid="pone-0091838-g001">Figure 1</xref>).</p><fig id="pone-0091838-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0091838.g001</object-id><label>Figure 1</label><caption><title>Selection of patients for the study.</title></caption><graphic xlink:href="pone.0091838.g001"/></fig><sec id="s3a"><title>Basal (Pre-Surgery) information in both populations</title><p>The characteristics of both populations and their co-morbidities are compared in <xref ref-type="table" rid="pone-0091838-t001">Table 1</xref>. Sex, co-morbidities, underlying conditions, APACHE II score, ASA score and EuroSCORE (4.04&#x000b1;2.5 in the E-lock group vs 4.07&#x000b1;2.5 in the CCC group: p&#x0200a;=&#x0200a;0.94) were similar in both groups of patients. The APACHE II score was respectively 8.89 (&#x000b1;2.7) for the E-lock and 8.86 (&#x000b1;2.5) for the Control Group, with no significant differences between them.</p><table-wrap id="pone-0091838-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0091838.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics and surgical variables of study patients in the overall population.</title></caption><alternatives><graphic id="pone-0091838-t001-1" xlink:href="pone.0091838.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ethanol N&#x0200a;=&#x0200a;113</td><td align="left" rowspan="1" colspan="1">Control N&#x0200a;=&#x0200a;87</td><td align="left" rowspan="1" colspan="1">p value</td></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1">
<bold>Preoperative</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean age in years (SD)</td><td align="left" rowspan="1" colspan="1">67.3 (13.1)</td><td align="left" rowspan="1" colspan="1">65.2 (14.3)</td><td align="left" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex (%)</td><td align="left" rowspan="1" colspan="1">62 (55)</td><td align="left" rowspan="1" colspan="1">47 (54)</td><td align="left" rowspan="1" colspan="1">0.90</td></tr><tr><td colspan="4" align="left" rowspan="1">Underlying conditions (%):</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="left" rowspan="1" colspan="1">16 (14.2)</td><td align="left" rowspan="1" colspan="1">13 (14.9)</td><td align="left" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">Congestive heart failure</td><td align="left" rowspan="1" colspan="1">15 (13.3)</td><td align="left" rowspan="1" colspan="1">7 (8.0)</td><td align="left" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">CNS disorder</td><td align="left" rowspan="1" colspan="1">2 (1.8)</td><td align="left" rowspan="1" colspan="1">3 (3.4)</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">COPD</td><td align="left" rowspan="1" colspan="1">15 (13.3)</td><td align="left" rowspan="1" colspan="1">22 (25.3)</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal dysfunction</td><td align="left" rowspan="1" colspan="1">7 (6.2)</td><td align="left" rowspan="1" colspan="1">9 (10.3)</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver disease</td><td align="left" rowspan="1" colspan="1">4 (3.5)</td><td align="left" rowspan="1" colspan="1">6 (6.9)</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">30 (26.5)</td><td align="left" rowspan="1" colspan="1">29 (33.3)</td><td align="left" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Peptic ulcer disease</td><td align="left" rowspan="1" colspan="1">2 (1.8)</td><td align="left" rowspan="1" colspan="1">3 (3.4)</td><td align="left" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Malignant neoplasm</td><td align="left" rowspan="1" colspan="1">12 (10.6)</td><td align="left" rowspan="1" colspan="1">4 (4.6)</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-fatal underlying disease (%)(McCabe criteria) <xref rid="pone.0091838-McCabe1" ref-type="bibr">[40]</xref>
</td><td align="left" rowspan="1" colspan="1">111 (98.2)</td><td align="left" rowspan="1" colspan="1">85 (97.7)</td><td align="left" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean comorbidity index (&#x000b1;SD) Charlson's criteria) <xref rid="pone.0091838-Charlson1" ref-type="bibr">[41]</xref>
</td><td align="left" rowspan="1" colspan="1">1.29 (1.64)</td><td align="left" rowspan="1" colspan="1">1.38 (1.32)</td><td align="left" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean Apache II score (&#x000b1;SD)</td><td align="left" rowspan="1" colspan="1">8.88 (2.7)</td><td align="left" rowspan="1" colspan="1">8.86 (2.59)</td><td align="left" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients with ASA Score &#x0003e;3 (%)</td><td align="left" rowspan="1" colspan="1">112 (99.1)</td><td align="left" rowspan="1" colspan="1">84 (96.6)</td><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean EUROSCORE<xref rid="pone.0091838-Nashef1" ref-type="bibr">[42]</xref> (&#x000b1;SD)</td><td align="left" rowspan="1" colspan="1">4.04 (2.5)</td><td align="left" rowspan="1" colspan="1">4.07 (2.5)</td><td align="left" rowspan="1" colspan="1">0.94</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>Operative data</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Valve replacement (%)</td><td align="left" rowspan="1" colspan="1">58 (51.3)</td><td align="left" rowspan="1" colspan="1">53 (60.9)</td><td align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery bypass grafting (CABG) (%)</td><td align="left" rowspan="1" colspan="1">30 (26.5)</td><td align="left" rowspan="1" colspan="1">16 (18.4)</td><td align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Mixed (valve and CABG) (%)</td><td align="left" rowspan="1" colspan="1">20 (17.7)</td><td align="left" rowspan="1" colspan="1">11 (12.6)</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean CPBT (min) (SD)</td><td align="left" rowspan="1" colspan="1">122.9(54.0)</td><td align="left" rowspan="1" colspan="1">117.1(63.6)</td><td align="left" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean aortic cross-clamp time (min) (SD)</td><td align="left" rowspan="1" colspan="1">80.3 (35.4)</td><td align="left" rowspan="1" colspan="1">75.1 (45.1)</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean total surgery time (min) (SD)</td><td align="left" rowspan="1" colspan="1">253.8 (78.6)</td><td align="left" rowspan="1" colspan="1">256.7 (88.5)</td><td align="left" rowspan="1" colspan="1">0.80</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Abbreviations: COPD: chronic obstructive pulmonary disease; CNS: Central Nervous System; CABG: coronary artery by-pass grafting; CPBT: cardiopulmonary by-pass time.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Data of the surgical procedure</title><p>Type of surgery, mean time on cardiopulmonary by-pass, aortic cross-clamp time and antimicrobial prophylaxis were similar in both groups (<xref ref-type="table" rid="pone-0091838-t001">Table 1</xref>).</p></sec><sec id="s3c"><title>Vascular access</title><p>Both populations showed no significant differences in the total number of catheters, mean number of catheters per patient, location of catheters, days of exposure to catheters, use of lipid or parenteral nutrition and other parameters (<xref ref-type="table" rid="pone-0091838-t002">Table 2</xref>).</p><table-wrap id="pone-0091838-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0091838.t002</object-id><label>Table 2</label><caption><title>Characteristics of Vascular Access in both groups.</title></caption><alternatives><graphic id="pone-0091838-t002-2" xlink:href="pone.0091838.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ethanol N&#x0200a;=&#x0200a;113</td><td align="left" rowspan="1" colspan="1">Control N&#x0200a;=&#x0200a;87</td><td align="left" rowspan="1" colspan="1">p value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total catheters (n)</td><td align="left" rowspan="1" colspan="1">179</td><td align="left" rowspan="1" colspan="1">144</td><td align="left" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Cultures taken (n)</td><td align="left" rowspan="1" colspan="1">1289</td><td align="left" rowspan="1" colspan="1">1147</td><td align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients with Positive cultures</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Total Catheter exposure (days)</td><td align="left" rowspan="1" colspan="1">955</td><td align="left" rowspan="1" colspan="1">805</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Days of catheter exposure. Median (IQR)</td><td align="left" rowspan="1" colspan="1">6 (4&#x02013;8)</td><td align="left" rowspan="1" colspan="1">7 (5&#x02013;9)</td><td align="left" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">Type of catheter (%):</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Conventional</td><td align="left" rowspan="1" colspan="1">122 (68.2%)</td><td align="left" rowspan="1" colspan="1">94 (65.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Swan-Ganz</td><td align="left" rowspan="1" colspan="1">57 (31.8)</td><td align="left" rowspan="1" colspan="1">50 (34.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Location (%):</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Jugular</td><td align="left" rowspan="1" colspan="1">172 (96.1)</td><td align="left" rowspan="1" colspan="1">141 (97.9)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Subclavian</td><td align="left" rowspan="1" colspan="1">7 (3.4)</td><td align="left" rowspan="1" colspan="1">3 (2.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Total Parenteral Nutrition (%)</td><td align="left" rowspan="1" colspan="1">6 (3.4)</td><td align="left" rowspan="1" colspan="1">6 (4.2)</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Reasons for catheter withdrawal (%):</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">End of use</td><td align="left" rowspan="1" colspan="1">166 (92.8)</td><td align="left" rowspan="1" colspan="1">135 (93.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Obstruction</td><td align="left" rowspan="1" colspan="1">5 (2.8)</td><td align="left" rowspan="1" colspan="1">4 (2.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Suspicion of infection</td><td align="left" rowspan="1" colspan="1">3 (1.7)</td><td align="left" rowspan="1" colspan="1">3 (2.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events</td><td align="left" rowspan="1" colspan="1">2 (1.1)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></sec><sec id="s3d"><title>Lock procedures</title><p>The lumens of catheters in the ethanol group were locked sequentially every 3 days with 1 ml of 70% ethanol solution. After the 2 hour locks, the lumens were flushed with 5 ml of normal saline.</p><p>The total number of locks (all catheters lumens) that were made with ethanol was 338, with a range that varied between 1 and 25 locks per patient (median 2.0). Dwell time was 2 hours, uniformly in all cases.</p></sec><sec id="s3e"><title>Primary endpoints</title><p>Post-surgical outcomes of both populations are summarized in <xref ref-type="table" rid="pone-0091838-t003">Table 3</xref>. The number of episodes of CR-BSI was 2 episodes in the ethanol group (2.1 episodes/1,000 days of exposure) and 4 episodes in the control group (5.0 episodes/1000 days of exposure). The calculated incidence rate ratio was 0.42 (95% confidence interval 0.04&#x02013;2.90), which implies a non-significant reduction of 58% for patients treated with ethanol locks (p&#x0200a;=&#x0200a;0.33). The episodes of CR-BSI occurred in days 4 to 44 postoperatively and the etiology of the episodes is shown in <xref ref-type="table" rid="pone-0091838-t003">Table 3</xref>.</p><table-wrap id="pone-0091838-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0091838.t003</object-id><label>Table 3</label><caption><title>Clinical outcome in all randomized patients</title></caption><alternatives><graphic id="pone-0091838-t003-3" xlink:href="pone.0091838.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ethanol N&#x0200a;=&#x0200a;113</td><td align="left" rowspan="1" colspan="1">Control N&#x0200a;=&#x0200a;87</td><td align="left" rowspan="1" colspan="1">p value</td></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1">
<bold>Catheter colonization:</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Overall (%)</td><td align="left" rowspan="1" colspan="1">39 (21.8%)</td><td align="left" rowspan="1" colspan="1">36 (25%)</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin (%)</td><td align="left" rowspan="1" colspan="1">30 (16.8)</td><td align="left" rowspan="1" colspan="1">32 (22.2)</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin colonization (density/1000 catheter-days)</td><td align="left" rowspan="1" colspan="1">39.52</td><td align="left" rowspan="1" colspan="1">49.53</td><td align="left" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">Hub (%)</td><td align="left" rowspan="1" colspan="1">4 (2.2)</td><td align="left" rowspan="1" colspan="1">3 (2.1)</td><td align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">Hub colonization (density/1000 catheter-days)</td><td align="left" rowspan="1" colspan="1">4.40</td><td align="left" rowspan="1" colspan="1">3.82</td><td align="left" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">Tip colonization (%)</td><td align="left" rowspan="1" colspan="1">14 (7.8)</td><td align="left" rowspan="1" colspan="1">6 (4.2)</td><td align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Tip colonization (density/1000 catheter-days)</td><td align="left" rowspan="1" colspan="1">15.26</td><td align="left" rowspan="1" colspan="1">8.0</td><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>CR-BSI:</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Episodes (%)</td><td align="left" rowspan="1" colspan="1">2 (1.8)</td><td align="left" rowspan="1" colspan="1">4 (4.6)</td><td align="left" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">CR-BSI Density per 1000 catheter-days</td><td align="left" rowspan="1" colspan="1">2.17</td><td align="left" rowspan="1" colspan="1">5.24</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>Other infections (%):</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Urinary tract infection</td><td align="left" rowspan="1" colspan="1">7 (6.2)</td><td align="left" rowspan="1" colspan="1">7 (8.0)</td><td align="left" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">Bacteremia</td><td align="left" rowspan="1" colspan="1">6 (5.5)</td><td align="left" rowspan="1" colspan="1">6 (7.1)</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Ventilator associated pneumonia</td><td align="left" rowspan="1" colspan="1">2 (1.8)</td><td align="left" rowspan="1" colspan="1">3 (3.4)</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Surgical Wound Infection</td><td align="left" rowspan="1" colspan="1">3 (2.7)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Clostridium difficile</italic>-infection</td><td align="left" rowspan="1" colspan="1">2 (1.8)</td><td align="left" rowspan="1" colspan="1">1 (1.1)</td><td align="left" rowspan="1" colspan="1">0.63</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>Days of Stay Median (IQR):</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU</td><td align="left" rowspan="1" colspan="1">5 (3&#x02013;7)</td><td align="left" rowspan="1" colspan="1">6 (3&#x02013;7)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital</td><td align="left" rowspan="1" colspan="1">15 (12&#x02013;25)</td><td align="left" rowspan="1" colspan="1">16 (13&#x02013;28)</td><td align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">Mortality in hospital (%)</td><td align="left" rowspan="1" colspan="1">7 (6.2)</td><td align="left" rowspan="1" colspan="1">7 (8.0)</td><td align="left" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">Overall DDD's of AA during hospital stay. Mean (SD)</td><td align="left" rowspan="1" colspan="1">7.99 (18.6)</td><td align="left" rowspan="1" colspan="1">9.11(16.5)</td><td align="left" rowspan="1" colspan="1">0.65</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>Abbreviations: IQR: interquartile range; DDDs: daily defined doses; AA: Antimicrobial Agents.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3f"><title>Secondary endpoints</title><p>We were not able to demonstrate differences in the secondary endpoints of the study (<xref ref-type="table" rid="pone-0091838-t003">Table 3</xref>), including days in the ICU and hospital stay, days of catheter exposure and number of colonized catheters. No differences were detected between both groups in the incidence of other infections, antibiotics consumption, incidence of CDI, ICU or hospital mortality (<xref ref-type="table" rid="pone-0091838-t003">Table 3</xref>).</p></sec><sec id="s3g"><title>Adverse events</title><p>The adverse events of both groups are summarized in <xref ref-type="table" rid="pone-0091838-t004">Table 4</xref>. Obstruction of catheters that required catheter withdrawal occurred in 5 patients in the ethanol group and in 4 patients in the control group (p&#x0200a;=&#x0200a;0.87) (<xref ref-type="table" rid="pone-0091838-t004">Table 4</xref>). In 7 patients the ethanol locks could not be completed, in five of them due to hemodynamic instability (high doses of inotropics). One catheter in the ethanol group had to be removed because of the rupture of 1 of the 3 lumens (<xref ref-type="table" rid="pone-0091838-t004">Table 4</xref>).</p><table-wrap id="pone-0091838-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0091838.t004</object-id><label>Table 4</label><caption><title>Adverse events.</title></caption><alternatives><graphic id="pone-0091838-t004-4" xlink:href="pone.0091838.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ethanol N&#x0200a;=&#x0200a;113</td><td align="left" rowspan="1" colspan="1">Control N&#x0200a;=&#x0200a;87</td><td align="left" rowspan="1" colspan="1">p value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Discontinuation of the study compound</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe immediate adverse events</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Rupture of the catheter lumen</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients with ALAT&#x02013;ASAT elevations (double than normal value)</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">0.91</td></tr></tbody></table></alternatives></table-wrap><p>In the five minutes following the flushing of the lock solutions, 2 patients in the ethanol group presented important adverse events. One had chest pain accompanied by high blood pressure, without any other hemodynamic or electrocardiographic changes. The chest pain disappeared rapidly after the catheter was withdrawn. The second patient developed intense headaches and photopsies. The flushing was stopped and the catheter withdrawn. The catheter tip from this patient was inappropriately placed in the upper jugular vein. The comparison of liver enzymes, ALAT and ASAT was not significantly different between both groups (<xref ref-type="table" rid="pone-0091838-t004">Table 4</xref>).</p></sec><sec id="s3h"><title>Microorganisms isolated from colonization and CR-BSI episodes</title><p>For the purpose of this study, all removed catheters were sent for culture to the Microbiology Department (314 of 323). Overall, 20 patients showed a positive semiquantitative count of the catheter tip. Of these, 14 belonged to the E-lock group, while 6 were in the CCC group (p&#x0200a;=&#x0200a;0.17).</p><p>Surveillance cultures of the peri-catheter skin and hubs were systematically done until catheter removal. The number of patients with one or more positive surveillance cultures was not significantly different in the population treated with ethanol (31/113) than in the conventional treatment population (26/87) (p&#x0200a;=&#x0200a;0.70).</p><p>The microorganisms present in significant counts in surveillance cultures are summarized in <xref ref-type="table" rid="pone-0091838-t005">Table 5</xref>. No significant differences were found in the microorganisms causing CR-BRSI or colonization in both groups.</p><table-wrap id="pone-0091838-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0091838.t005</object-id><label>Table 5</label><caption><title>Microorganisms present in significant counts in surveillance cultures and CR-BSI.</title></caption><alternatives><graphic id="pone-0091838-t005-5" xlink:href="pone.0091838.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ethanol N&#x0200a;=&#x0200a;113</td><td align="left" rowspan="1" colspan="1">Control N&#x02212;87</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CR-BSI (6):</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">Gram positive cocci (%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (1.14)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Enterobacteriaceae</italic> (%)</td><td align="left" rowspan="1" colspan="1">2 (1.76)</td><td align="left" rowspan="1" colspan="1">2 (2.29)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GNNFR (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 (1.14)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fungi (%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Colonized patients (57) (1species per patient):</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1">Gram positive cocci (%)</td><td align="left" rowspan="1" colspan="1">35 (30.97)</td><td align="left" rowspan="1" colspan="1">27 (31.03)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Enterobacteriaceae (%)</td><td align="left" rowspan="1" colspan="1">4 (3.53)</td><td align="left" rowspan="1" colspan="1">2 (2.29)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GNNFR (%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (1.14)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fungi (%)</td><td align="left" rowspan="1" colspan="1">1 (0.88)</td><td align="left" rowspan="1" colspan="1">1 (1.14)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>GNNFR: Gram negative non-fermenting rods.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3i"><title>Multivariate analysis</title><p>In the multivariate analysis the difference of the incidence density of CR-BSI, between the E-lock and CCC groups was not significant. The number of patients needed to be treated with ethanol-locks to prevent one CR-BSI episode was 345.</p></sec></sec><sec id="s4"><title>Discussion</title><p>Our study shows that despite a trend in the reduction of CR-BSI, the use of ethanol locks for the prevention of CR-BSI in patients undergoing MHS should not be recommended. It is cumbersome and associated with serious adverse events.</p><p>In recent years, different campaigns have emphasized the need to drastically reduce CR-BSI and have set zero tolerance concept to those infections <xref rid="pone.0091838-Pronovost1" ref-type="bibr">[8]</xref>, <xref rid="pone.0091838-Berenholtz1" ref-type="bibr">[22]</xref>. Achieving and maintaining the zero incidence, however, proved to be a very difficult or impossible task, even in situations and institutions that made very serious and obstinate efforts <xref rid="pone.0091838-Patil1" ref-type="bibr">[23]</xref>, <xref rid="pone.0091838-vanderKooi1" ref-type="bibr">[24]</xref>. The search for alternative, non-educational procedures to contribute to a zero incidence remains pertinent, particularly in populations with many catheters and at a high risk for CR-BSI, as it is the case of patients undergoing MHS <xref rid="pone.0091838-Bouza2" ref-type="bibr">[25]</xref>.</p><p>The use of high concentrations of antibiotics in the catheter lumens (lock-therapy) proved to be effective both in the conservative treatment management of infected catheters <xref rid="pone.0091838-Kim2" ref-type="bibr">[11]</xref>, <xref rid="pone.0091838-Onder1" ref-type="bibr">[26]</xref> and also as a prophylactic approach in certain situations <xref rid="pone.0091838-Yahav1" ref-type="bibr">[27]</xref>, <xref rid="pone.0091838-Ghannoum1" ref-type="bibr">[28]</xref>. Antibiotics, however, have different activities against different microorganisms, their penetration in the catheter biofilm is highly variable and the long-term use of antibiotic-locks, mainly in prophylaxis, may lead to the development of antimicrobial resistance <xref rid="pone.0091838-Landry1" ref-type="bibr">[13]</xref>, <xref rid="pone.0091838-Venditto1" ref-type="bibr">[29]</xref>.</p><p>Ethanol is easy to produce and has a broad spectrum of antimicrobial activity, including bacteria and <italic>Candida</italic>
<xref rid="pone.0091838-Ghannoum1" ref-type="bibr">[28]</xref>, <xref rid="pone.0091838-Shenep1" ref-type="bibr">[30]</xref>&#x02013;<xref rid="pone.0091838-Raad1" ref-type="bibr">[32]</xref>. Studies of ethanol lock as a therapeutic agent for the treatment of CR-BSI are frequently based on case reports or very short series <xref rid="pone.0091838-Valentine1" ref-type="bibr">[33]</xref> and usually selected for treatment of episodes caused by &#x0201c;easy to treat&#x0201d; microorganisms such as Coagulase Negative Staphylococcus. Under these circumstances, eradication of infections were obtained in up to 86% of the episodes in the McGrath's study <xref rid="pone.0091838-McGrath1" ref-type="bibr">[17]</xref>. The tolerance to alcohol in those studies was generally good <xref rid="pone.0091838-Valentine1" ref-type="bibr">[33]</xref>, <xref rid="pone.0091838-John1" ref-type="bibr">[34]</xref> but thrombosis and other adverse events were reported <xref rid="pone.0091838-Wales1" ref-type="bibr">[15]</xref>, <xref rid="pone.0091838-Wong1" ref-type="bibr">[35]</xref>.</p><p>Data regarding the efficacy of ethanol locks in the prevention of CR-BSI is scarce. A meta-analysis in pediatric patients with short bowel syndrome and long-term catheters carried out by Oliveira et al <xref rid="pone.0091838-Oliveira1" ref-type="bibr">[16]</xref>, found 4 retrospective studies in this population. In comparison with heparin-locks, ethanol locks reduced the CR-BSI-rate by 81% and the need of catheter replacements by 72%. Overall, 108 to 150 catheter days of ethanol exposure were necessary to prevent one CR-BSI episode and 122 to 689 days of exposure prevented one catheter replacement.</p><p>In the case of hematologic patients with tunneled catheters, a randomized, double-blind, placebo-controlled trial compared ethanol locks for 15 minutes per day with a placebo. No significant differences were found between both groups in the incidence of CR-BSI, but more patients receiving ethanol discontinued lock-therapy (11 of 226 versus 1 of 222; p&#x0200a;=&#x0200a;0.006) or continued with decreased lock-frequency (10 of 226 versus 0 of 222; p&#x0200a;=&#x0200a;0.002) due to non-severe adverse events. In patients allocated to ethanol locks, one device had to be removed because of the rupture of 1 of the 3 catheter lumens. Facial flushing occurred in 39 out of the 226 patients with ethanol, compared to 17 out of the 222 patients with placebo (p&#x0003c;0.001) and feelings of dizziness/drowsiness occurred in 41 and 10 patients with ethanol or placebo respectively (p&#x0003c;0.001) <xref rid="pone.0091838-Slobbe1" ref-type="bibr">[36]</xref>.</p><p>Occasional information indirectly suggest the effectiveness of ethanol in preventing infections in the subgroups of patients on Total Parenteral Nutrition <xref rid="pone.0091838-Wales1" ref-type="bibr">[15]</xref>, <xref rid="pone.0091838-John1" ref-type="bibr">[34]</xref> and in other patients <xref rid="pone.0091838-Broom2" ref-type="bibr">[37]</xref> but different adverse events including thrombosis and catheter dysfunction were also reported <xref rid="pone.0091838-Wales1" ref-type="bibr">[15]</xref>, <xref rid="pone.0091838-Wong1" ref-type="bibr">[35]</xref>, <xref rid="pone.0091838-Heng1" ref-type="bibr">[38]</xref>.</p><p>Our population, of patients undergoing Major Heart Surgery, is a uniform but different population, frequently hemodynamically unstable and with highly needed central lines. The number of CR-BSI was reduced by 58% in patients receiving ethanol in our study, but the differences did not reach statistical significance, probably due to the early stop of our study and the consequent low power. Our calculations show that to prevent an episode of CR-BSI in our patients, 345 cases would have to receive prophylactic ethanol.</p><p>We selected as a primary end-point CR-BSI instead of CLABSI (Central Line Associated Bloodstream Infection). CLABSI is an approximate concept useful for epidemiological surveillance, while CR-BSI requires the confirmation with catheter cultures of the etiology and origin of CR-BSI. In our study the culture of catheters was uniformly performed upon withdrawal and the risk to miss cases was totally avoided. Furthermore, we have recently demonstrated that the trends of CLABSI and CR-BSI in the very unit in which we carried out this study <xref rid="pone.0091838-RodriguezCreixems1" ref-type="bibr">[39]</xref>.</p><p>The principal limitation of this trial is that we only enrolled the population undergoing Major Heart Surgery and this data cannot necessarily be extrapolated to other populations. Also very importantly, due to the detection of adverse events in the ethanol branch, we had to stop the trial after 10 months and our study was underpowered to detect a significant reduction of the CR-BSI episodes.</p><p>The limited and doubtful reduction of CR-BSI with the use of ethanol locks, the adverse events, the workload of the procedure for the nursing staff, the need for a high frequency of catheter manipulation and the requirement to lock highly needed lines during 2 hours, were among the reasons to stop our study. We do not recommend further studies with ethanol lock in the prevention of CR-BSI in patients following MHS.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0091838.s001"><label>Checklist S1</label><caption><p>
<bold>CONSORT Checklist.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0091838.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0091838.s002"><label>Protocol S1</label><caption><p>
<bold>Trial Protocol.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0091838.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0091838.s003"><label>Protocol S2</label><caption><p>
<bold>Spanish Translation of Protocol S1.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0091838.s003.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Laurence Baron for his help in the preparation of the English version of the manuscript and Cristina Fern&#x000e1;ndez for the statistical analysis.</p></ack><ref-list><title>References</title><ref id="pone.0091838-Kollef1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Kollef</surname><given-names>MH</given-names></name>, <name><surname>Sharpless</surname><given-names>L</given-names></name>, <name><surname>Vlasnik</surname><given-names>J</given-names></name>, <name><surname>Pasque</surname><given-names>C</given-names></name>, <name><surname>Murphy</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>1997</year>) <article-title>The impact of nosocomial infections on patient outcomes following cardiac surgery</article-title>. <source>Chest</source>
<volume>112</volume>: <fpage>666</fpage>&#x02013;<lpage>675</lpage>.<pub-id pub-id-type="pmid">9315799</pub-id></mixed-citation></ref><ref id="pone.0091838-Rebollo1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Rebollo</surname><given-names>MH</given-names></name>, <name><surname>Bernal</surname><given-names>JM</given-names></name>, <name><surname>Llorca</surname><given-names>J</given-names></name>, <name><surname>Rabasa</surname><given-names>JM</given-names></name>, <name><surname>Revuelta</surname><given-names>JM</given-names></name> (<year>1996</year>) <article-title>Nosocomial infections in patients having cardiovascular operations: a multivariate analysis of risk factors</article-title>. <source>J Thorac Cardiovasc Surg</source>
<volume>112</volume>: <fpage>908</fpage>&#x02013;<lpage>913</lpage>.<pub-id pub-id-type="pmid">8873716</pub-id></mixed-citation></ref><ref id="pone.0091838-LeGuillou1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Le Guillou</surname><given-names>V</given-names></name>, <name><surname>Tavolacci</surname><given-names>MP</given-names></name>, <name><surname>Baste</surname><given-names>JM</given-names></name>, <name><surname>Hubscher</surname><given-names>C</given-names></name>, <name><surname>Bedoit</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Surgical site infection after central venous catheter-related infection in cardiac surgery. Analysis of a cohort of 7557 patients</article-title>. <source>J Hosp Infect</source>
<volume>79</volume>: <fpage>236</fpage>&#x02013;<lpage>241</lpage>.<pub-id pub-id-type="pmid">21899923</pub-id></mixed-citation></ref><ref id="pone.0091838-Bouza1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Bouza</surname><given-names>E</given-names></name>, <name><surname>San Juan</surname><given-names>R</given-names></name>, <name><surname>Munoz</surname><given-names>P</given-names></name>, <name><surname>Pascau</surname><given-names>J</given-names></name>, <name><surname>Voss</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>A European perspective on intravascular catheter-related infections: report on the microbiology workload, aetiology and antimicrobial susceptibility (ESGNI-005 Study)</article-title>. <source>Clin Microbiol Infect</source>
<volume>10</volume>: <fpage>838</fpage>&#x02013;<lpage>842</lpage>.<pub-id pub-id-type="pmid">15355416</pub-id></mixed-citation></ref><ref id="pone.0091838-Zack1"><label>5</label><mixed-citation publication-type="journal">Zack J (2008) Zeroing in on zero tolerance for central line-associated bacteremia. Am J Infect Control <volume>36</volume>: : S176 e171&#x02013;172.</mixed-citation></ref><ref id="pone.0091838-Kim1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Kim</surname><given-names>JS</given-names></name>, <name><surname>Holtom</surname><given-names>P</given-names></name>, <name><surname>Vigen</surname><given-names>C</given-names></name> (<year>2011</year>) <article-title>Reduction of catheter-related bloodstream infections through the use of a central venous line bundle: epidemiologic and economic consequences</article-title>. <source>Am J Infect Control</source>
<volume>39</volume>: <fpage>640</fpage>&#x02013;<lpage>646</lpage>.<pub-id pub-id-type="pmid">21641088</pub-id></mixed-citation></ref><ref id="pone.0091838-Betjes1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Betjes</surname><given-names>MG</given-names></name> (<year>2011</year>) <article-title>Prevention of catheter-related bloodstream infection in patients on hemodialysis</article-title>. <source>Nat Rev Nephrol</source>
<volume>7</volume>: <fpage>257</fpage>&#x02013;<lpage>265</lpage>.<pub-id pub-id-type="pmid">21423251</pub-id></mixed-citation></ref><ref id="pone.0091838-Pronovost1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Pronovost</surname><given-names>P</given-names></name>, <name><surname>Needham</surname><given-names>D</given-names></name>, <name><surname>Berenholtz</surname><given-names>S</given-names></name>, <name><surname>Sinopoli</surname><given-names>D</given-names></name>, <name><surname>Chu</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>An intervention to decrease catheter-related bloodstream infections in the ICU</article-title>. <source>N Engl J Med</source>
<volume>355</volume>: <fpage>2725</fpage>&#x02013;<lpage>2732</lpage>.<pub-id pub-id-type="pmid">17192537</pub-id></mixed-citation></ref><ref id="pone.0091838-PalomarMartinez1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Palomar Martinez</surname><given-names>M</given-names></name>, <name><surname>Alvarez Lerma</surname><given-names>F</given-names></name>, <name><surname>Riera Badia</surname><given-names>MA</given-names></name>, <name><surname>Leon Gil</surname><given-names>C</given-names></name>, <name><surname>Lopez Pueyo</surname><given-names>MJ</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>[Prevention of bacteriema related with ICU catheters by multifactorial intervention: a report of the pilot study]</article-title>. <source>Med Intensiva</source>
<volume>34</volume>: <fpage>581</fpage>&#x02013;<lpage>589</lpage>.<pub-id pub-id-type="pmid">21041004</pub-id></mixed-citation></ref><ref id="pone.0091838-Opilla1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Opilla</surname><given-names>MT</given-names></name>, <name><surname>Kirby</surname><given-names>DF</given-names></name>, <name><surname>Edmond</surname><given-names>MB</given-names></name> (<year>2007</year>) <article-title>Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>
<volume>31</volume>: <fpage>302</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="pmid">17595439</pub-id></mixed-citation></ref><ref id="pone.0091838-Kim2"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Kim</surname><given-names>EY</given-names></name>, <name><surname>Saunders</surname><given-names>P</given-names></name>, <name><surname>Yousefzadeh</surname><given-names>N</given-names></name> (<year>2010</year>) <article-title>Usefulness of anti-infective lock solutions for catheter-related bloodstream infections</article-title>. <source>Mt Sinai J Med</source>
<volume>77</volume>: <fpage>549</fpage>&#x02013;<lpage>558</lpage>.<pub-id pub-id-type="pmid">20960556</pub-id></mixed-citation></ref><ref id="pone.0091838-Huang1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Huang</surname><given-names>EY</given-names></name>, <name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Abdullah</surname><given-names>F</given-names></name>, <name><surname>Aspelund</surname><given-names>G</given-names></name>, <name><surname>Barnhart</surname><given-names>DC</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Strategies for the prevention of central venous catheter infections: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review</article-title>. <source>J Pediatr Surg</source>
<volume>46</volume>: <fpage>2000</fpage>&#x02013;<lpage>2011</lpage>.<pub-id pub-id-type="pmid">22008341</pub-id></mixed-citation></ref><ref id="pone.0091838-Landry1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Landry</surname><given-names>DL</given-names></name>, <name><surname>Braden</surname><given-names>GL</given-names></name>, <name><surname>Gobeille</surname><given-names>SL</given-names></name>, <name><surname>Haessler</surname><given-names>SD</given-names></name>, <name><surname>Vaidya</surname><given-names>CK</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis</article-title>. <source>Clin J Am Soc Nephrol</source>
<volume>5</volume>: <fpage>1799</fpage>&#x02013;<lpage>1804</lpage>.<pub-id pub-id-type="pmid">20595689</pub-id></mixed-citation></ref><ref id="pone.0091838-Rajpurkar1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Rajpurkar</surname><given-names>M</given-names></name>, <name><surname>Boldt-Macdonald</surname><given-names>K</given-names></name>, <name><surname>McLenon</surname><given-names>R</given-names></name>, <name><surname>Callaghan</surname><given-names>MU</given-names></name>, <name><surname>Chitlur</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Ethanol lock therapy for the treatment of catheter-related infections in haemophilia patients</article-title>. <source>Haemophilia</source>
<volume>15</volume>: <fpage>1267</fpage>&#x02013;<lpage>1271</lpage>.<pub-id pub-id-type="pmid">19659937</pub-id></mixed-citation></ref><ref id="pone.0091838-Wales1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Wales</surname><given-names>PW</given-names></name>, <name><surname>Kosar</surname><given-names>C</given-names></name>, <name><surname>Carricato</surname><given-names>M</given-names></name>, <name><surname>de Silva</surname><given-names>N</given-names></name>, <name><surname>Lang</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients with intestinal failure: preliminary experience</article-title>. <source>J Pediatr Surg</source>
<volume>46</volume>: <fpage>951</fpage>&#x02013;<lpage>956</lpage>.<pub-id pub-id-type="pmid">21616259</pub-id></mixed-citation></ref><ref id="pone.0091838-Oliveira1"><label>16</label><mixed-citation publication-type="other">Oliveira C, Nasr A, Brindle M, Wales PW (2012) Ethanol Locks to Prevent Catheter-Related Bloodstream Infections in Parenteral Nutrition: A Meta-Analysis. Pediatrics.</mixed-citation></ref><ref id="pone.0091838-McGrath1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>McGrath</surname><given-names>EJ</given-names></name>, <name><surname>Salloum</surname><given-names>R</given-names></name>, <name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Jiang</surname><given-names>Y</given-names></name>, <name><surname>Boldt-MacDonald</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Short-dwell ethanol lock therapy in children is associated with increased clearance of central line-associated bloodstream infections</article-title>. <source>Clin Pediatr (Phila)</source>
<volume>50</volume>: <fpage>943</fpage>&#x02013;<lpage>951</lpage>.<pub-id pub-id-type="pmid">21622689</pub-id></mixed-citation></ref><ref id="pone.0091838-Broom1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Broom</surname><given-names>J</given-names></name>, <name><surname>Woods</surname><given-names>M</given-names></name>, <name><surname>Allworth</surname><given-names>A</given-names></name>, <name><surname>McCarthy</surname><given-names>J</given-names></name>, <name><surname>Faoagali</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Ethanol lock therapy to treat tunnelled central venous catheter-associated blood stream infections: results from a prospective trial</article-title>. <source>Scand J Infect Dis</source>
<volume>40</volume>: <fpage>399</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">18418801</pub-id></mixed-citation></ref><ref id="pone.0091838-OGrady1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>O'Grady</surname><given-names>NP</given-names></name>, <name><surname>Alexander</surname><given-names>M</given-names></name>, <name><surname>Burns</surname><given-names>LA</given-names></name>, <name><surname>Dellinger</surname><given-names>EP</given-names></name>, <name><surname>Garland</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Guidelines for the prevention of intravascular catheter-related infections</article-title>. <source>Am J Infect Control</source>
<volume>39</volume>: <fpage>S1</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">21511081</pub-id></mixed-citation></ref><ref id="pone.0091838-Maki1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Maki</surname><given-names>DG</given-names></name>, <name><surname>Weise</surname><given-names>CE</given-names></name>, <name><surname>Sarafin</surname><given-names>HW</given-names></name> (<year>1977</year>) <article-title>A semiquantitative culture method for identifying intravenous-catheter-related infection</article-title>. <source>N Engl J Med</source>
<volume>296</volume>: <fpage>1305</fpage>&#x02013;<lpage>1309</lpage>.<pub-id pub-id-type="pmid">323710</pub-id></mixed-citation></ref><ref id="pone.0091838-Weller1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Weller</surname><given-names>C</given-names></name>, <name><surname>McNeil</surname><given-names>J</given-names></name> (<year>2010</year>) <article-title>CONSORT 2010 statement: updated guidelines can improve wound care</article-title>. <source>J Wound Care</source>
<volume>19</volume>: <fpage>347</fpage>&#x02013;<lpage>353</lpage>.<pub-id pub-id-type="pmid">20852507</pub-id></mixed-citation></ref><ref id="pone.0091838-Berenholtz1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Berenholtz</surname><given-names>SM</given-names></name>, <name><surname>Pronovost</surname><given-names>PJ</given-names></name>, <name><surname>Lipsett</surname><given-names>PA</given-names></name>, <name><surname>Hobson</surname><given-names>D</given-names></name>, <name><surname>Earsing</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Eliminating catheter-related bloodstream infections in the intensive care unit</article-title>. <source>Crit Care Med</source>
<volume>32</volume>: <fpage>2014</fpage>&#x02013;<lpage>2020</lpage>.<pub-id pub-id-type="pmid">15483409</pub-id></mixed-citation></ref><ref id="pone.0091838-Patil1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Patil</surname><given-names>HV</given-names></name>, <name><surname>Patil</surname><given-names>VC</given-names></name>, <name><surname>Ramteerthkar</surname><given-names>MN</given-names></name>, <name><surname>Kulkarni</surname><given-names>RD</given-names></name> (<year>2011</year>) <article-title>Central venous catheter-related bloodstream infections in the intensive care unit</article-title>. <source>Indian J Crit Care Med</source>
<volume>15</volume>: <fpage>213</fpage>&#x02013;<lpage>223</lpage>.<pub-id pub-id-type="pmid">22346032</pub-id></mixed-citation></ref><ref id="pone.0091838-vanderKooi1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>van der Kooi</surname><given-names>TI</given-names></name>, <name><surname>Wille</surname><given-names>JC</given-names></name>, <name><surname>van Benthem</surname><given-names>BH</given-names></name> (<year>2012</year>) <article-title>Catheter application, insertion vein and length of ICU stay prior to insertion affect the risk of catheter-related bloodstream infection</article-title>. <source>J Hosp Infect</source>
<volume>80</volume>: <fpage>238</fpage>&#x02013;<lpage>244</lpage>.<pub-id pub-id-type="pmid">22243832</pub-id></mixed-citation></ref><ref id="pone.0091838-Bouza2"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Bouza</surname><given-names>E</given-names></name>, <name><surname>Munoz</surname><given-names>P</given-names></name>, <name><surname>Burillo</surname><given-names>A</given-names></name>, <name><surname>Lopez-Rodriguez</surname><given-names>J</given-names></name>, <name><surname>Fernandez-Perez</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>The challenge of anticipating catheter tip colonization in major heart surgery patients in the intensive care unit: are surface cultures useful?</article-title>
<source>Crit Care Med</source>
<volume>33</volume>: <fpage>1953</fpage>&#x02013;<lpage>1960</lpage>.<pub-id pub-id-type="pmid">16148465</pub-id></mixed-citation></ref><ref id="pone.0091838-Onder1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Onder</surname><given-names>AM</given-names></name>, <name><surname>Billings</surname><given-names>A</given-names></name>, <name><surname>Chandar</surname><given-names>J</given-names></name>, <name><surname>Francoeur</surname><given-names>D</given-names></name>, <name><surname>Simon</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>PREFABL: predictors of failure of antibiotic locks for the treatment of catheter-related bacteraemia</article-title>. <source>Nephrol Dial Transplant</source>
<volume>25</volume>: <fpage>3686</fpage>&#x02013;<lpage>3693</lpage>.<pub-id pub-id-type="pmid">20501464</pub-id></mixed-citation></ref><ref id="pone.0091838-Yahav1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Yahav</surname><given-names>D</given-names></name>, <name><surname>Rozen-Zvi</surname><given-names>B</given-names></name>, <name><surname>Gafter-Gvili</surname><given-names>A</given-names></name>, <name><surname>Leibovici</surname><given-names>L</given-names></name>, <name><surname>Gafter</surname><given-names>U</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials</article-title>. <source>Clin Infect Dis</source>
<volume>47</volume>: <fpage>83</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">18498236</pub-id></mixed-citation></ref><ref id="pone.0091838-Ghannoum1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Ghannoum</surname><given-names>MA</given-names></name>, <name><surname>Isham</surname><given-names>N</given-names></name>, <name><surname>Jacobs</surname><given-names>MR</given-names></name> (<year>2011</year>) <article-title>Antimicrobial activity of B-Lock against bacterial and Candida spp. causing catheter-related bloodstream infections</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>55</volume>: <fpage>4430</fpage>&#x02013;<lpage>4431</lpage>.<pub-id pub-id-type="pmid">21730123</pub-id></mixed-citation></ref><ref id="pone.0091838-Venditto1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Venditto</surname><given-names>M</given-names></name>, <name><surname>du Montcel</surname><given-names>ST</given-names></name>, <name><surname>Robert</surname><given-names>J</given-names></name>, <name><surname>Trystam</surname><given-names>D</given-names></name>, <name><surname>Dighiero</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Effect of catheter-lock solutions on catheter-related infection and inflammatory syndrome in hemodialysis patients: heparin versus citrate 46% versus heparin/gentamicin</article-title>. <source>Blood Purif</source>
<volume>29</volume>: <fpage>268</fpage>&#x02013;<lpage>273</lpage>.<pub-id pub-id-type="pmid">20068292</pub-id></mixed-citation></ref><ref id="pone.0091838-Shenep1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Shenep</surname><given-names>LE</given-names></name>, <name><surname>Shenep</surname><given-names>MA</given-names></name>, <name><surname>Cheatham</surname><given-names>W</given-names></name>, <name><surname>Hoffman</surname><given-names>JM</given-names></name>, <name><surname>Hale</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Efficacy of intravascular catheter lock solutions containing preservatives in the prevention of microbial colonization</article-title>. <source>J Hosp Infect</source>
<volume>79</volume>: <fpage>317</fpage>&#x02013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">21945067</pub-id></mixed-citation></ref><ref id="pone.0091838-Blackwood1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Blackwood</surname><given-names>RA</given-names></name>, <name><surname>Klein</surname><given-names>KC</given-names></name>, <name><surname>Micel</surname><given-names>LN</given-names></name>, <name><surname>Willers</surname><given-names>ML</given-names></name>, <name><surname>Mody</surname><given-names>RJ</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Ethanol locks therapy for resolution of fungal catheter infections</article-title>. <source>Pediatr Infect Dis J</source>
<volume>30</volume>: <fpage>1105</fpage>&#x02013;<lpage>1107</lpage>.<pub-id pub-id-type="pmid">21844829</pub-id></mixed-citation></ref><ref id="pone.0091838-Raad1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Raad</surname><given-names>I</given-names></name>, <name><surname>Hanna</surname><given-names>H</given-names></name>, <name><surname>Dvorak</surname><given-names>T</given-names></name>, <name><surname>Chaiban</surname><given-names>G</given-names></name>, <name><surname>Hachem</surname><given-names>R</given-names></name> (<year>2007</year>) <article-title>Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>51</volume>: <fpage>78</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">17074799</pub-id></mixed-citation></ref><ref id="pone.0091838-Valentine1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Valentine</surname><given-names>KM</given-names></name> (<year>2011</year>) <article-title>Ethanol lock therapy for catheter-associated blood stream infections in a pediatric intensive care unit</article-title>. <source>Pediatr Crit Care Med</source>
<volume>12</volume>: <fpage>e292</fpage>&#x02013;<lpage>296</lpage>.<pub-id pub-id-type="pmid">21499184</pub-id></mixed-citation></ref><ref id="pone.0091838-John1"><label>34</label><mixed-citation publication-type="other">John BK, Khan MA, Speerhas R, Rhoda K, Hamilton C, <etal>et al</etal>.. (2011) Ethanol Lock Therapy in Reducing Catheter-Related Bloodstream Infections in Adult Home Parenteral Nutrition Patients: Results of a Retrospective Study. JPEN J Parenter Enteral Nutr.</mixed-citation></ref><ref id="pone.0091838-Wong1"><label>35</label><mixed-citation publication-type="other">Wong T, Clifford V, McCallum Z, Shalley H, Peterkin M, <etal>et al</etal>.. (2011) Central Venous Catheter Thrombosis Associated With 70% Ethanol Locks in Pediatric Intestinal Failure Patients on Home Parenteral Nutrition: A Case Series. JPEN J Parenter Enteral Nutr.</mixed-citation></ref><ref id="pone.0091838-Slobbe1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Slobbe</surname><given-names>L</given-names></name>, <name><surname>Doorduijn</surname><given-names>JK</given-names></name>, <name><surname>Lugtenburg</surname><given-names>PJ</given-names></name>, <name><surname>El Barzouhi</surname><given-names>A</given-names></name>, <name><surname>Boersma</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial</article-title>. <source>PLoS One</source>
<volume>5</volume>: <fpage>e10840</fpage>.<pub-id pub-id-type="pmid">20520776</pub-id></mixed-citation></ref><ref id="pone.0091838-Broom2"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Broom</surname><given-names>JK</given-names></name>, <name><surname>Krishnasamy</surname><given-names>R</given-names></name>, <name><surname>Hawley</surname><given-names>CM</given-names></name>, <name><surname>Playford</surname><given-names>EG</given-names></name>, <name><surname>Johnson</surname><given-names>DW</given-names></name> (<year>2012</year>) <article-title>A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients&#x02014;the HEALTHY-CATH trial</article-title>. <source>BMC Nephrol</source>
<volume>13</volume>: <fpage>146</fpage>.<pub-id pub-id-type="pmid">23121768</pub-id></mixed-citation></ref><ref id="pone.0091838-Heng1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Heng</surname><given-names>AE</given-names></name>, <name><surname>Abdelkader</surname><given-names>MH</given-names></name>, <name><surname>Diaconita</surname><given-names>M</given-names></name>, <name><surname>Nony</surname><given-names>A</given-names></name>, <name><surname>Guerraoui</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Impact of short term use of interdialytic 60% ethanol lock solution on tunneled silicone catheter dysfunction</article-title>. <source>Clin Nephrol</source>
<volume>75</volume>: <fpage>534</fpage>&#x02013;<lpage>541</lpage>.<pub-id pub-id-type="pmid">21612757</pub-id></mixed-citation></ref><ref id="pone.0091838-RodriguezCreixems1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Rodriguez-Creixems</surname><given-names>M</given-names></name>, <name><surname>Munoz</surname><given-names>P</given-names></name>, <name><surname>Martin-Rabadan</surname><given-names>P</given-names></name>, <name><surname>Cercenado</surname><given-names>E</given-names></name>, <name><surname>Guembe</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Evolution and aetiological shift of catheter-related bloodstream infection in a whole institution: the microbiology department may act as a watchtower</article-title>. <source>Clin Microbiol Infect</source>
<volume>19</volume>: <fpage>845</fpage>&#x02013;<lpage>851</lpage>.<pub-id pub-id-type="pmid">23565810</pub-id></mixed-citation></ref><ref id="pone.0091838-McCabe1"><label>40</label><mixed-citation publication-type="journal">
<name><surname>McCabe</surname><given-names>W</given-names></name>, <name><surname>Jackson</surname><given-names>GG</given-names></name> (<year>1962</year>) <article-title>Gram-negative bacteremia, I: etiology and ecology</article-title>. <source>Arch Inter Med</source>
<volume>110</volume>: <fpage>847</fpage>&#x02013;<lpage>55</lpage>.</mixed-citation></ref><ref id="pone.0091838-Charlson1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Charlson</surname><given-names>ME</given-names></name>, <name><surname>Pompei</surname><given-names>P</given-names></name>, <name><surname>Ales</surname><given-names>KL</given-names></name>, <name><surname>MacKenzie</surname><given-names>CR</given-names></name> (<year>1987</year>) <article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title>. <source>J Chronic Dis</source>
<volume>40</volume>: <fpage>373</fpage>&#x02013;<lpage>383</lpage>.<pub-id pub-id-type="pmid">3558716</pub-id></mixed-citation></ref><ref id="pone.0091838-Nashef1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Nashef</surname><given-names>SA</given-names></name>, <name><surname>Roques</surname><given-names>F</given-names></name>, <name><surname>Michel</surname><given-names>P</given-names></name>, <name><surname>Gauducheau</surname><given-names>E</given-names></name>, <name><surname>Lemeshow</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>European system for cardiac operative risk evaluation (EuroSCORE)</article-title>. <source>Eur J Cardiothorac Surg</source>
<volume>16</volume>: <fpage>9</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">10456395</pub-id></mixed-citation></ref></ref-list></back></article>